Drug Monograph

Drug/Drug Class:	**Linzess® (linaclotide) gelatin coated capsule/ GI Motility Agents**
Prepared for:	MO HealthNet
Prepared by:	Conduent-Heritage

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Linzess® is now available in a capsule that contains 72 mg linaclotide respectively.
Manufacturer:	Allergan USA Inc., Irvince, CA 92612
Indications:	Linzess® is indicated in adults for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
Costs:	$11.78 per capsule of Linzess®. Wholesale Acquisition Cost
Summary of Findings:	This drug is being considered for inclusion in the state specific Preferred Drug List as a preferred agent
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Under Solicitation ☐ Appropriate Indications ☒ Preferred

Prepared By: Luke Boehmer Pharm.D.
Date: May 15, 2017

© 2017 Conduent Business Services, LLC All Rights Reserved.